| Parmar, Deven |
NCT05515367: A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study) |
|
|
| Recruiting | 4 | 1004 | RoW | Desidustat | Zydus Lifesciences Limited | Chronic Kidney Diseases, Anemia of Chronic Kidney Disease | 05/24 | 08/25 | | |
NCT05872269: A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities |
|
|
| Recruiting | 4 | 1500 | RoW | Saroglitazar | Zydus Lifesciences Limited | NAFLD, Obesity, Type 2 Diabetes, Dyslipidemias, Metabolic Syndrome | 01/25 | 06/25 | | |
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis |
|
|
| Recruiting | 3 | 150 | US, RoW | Saroglitazar Magnesium 1 mg | Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 04/27 | 07/27 | | |
NCT05283837: A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) |
|
|
| Completed | 3 | 268 | RoW | Pertuzumab (ZRC-3277), Pertuzumab (Perjeta®) | Zydus Lifesciences Limited | Metastatic Breast Cancer | 09/23 | 09/23 | | |
| Active, not recruiting | 2/3 | 186 | NA | Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo | Zydus Therapeutics Inc., Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 05/25 | 05/25 | | |
NCT03639623: Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD) |
|
|
| Completed | 2 | 20 | US | Saroglitazar, Not any | Zydus Therapeutics Inc. | Liver Transplant; Complications, NAFLD | 12/21 | 12/21 | | |
| Active, not recruiting | 2 | 180 | US, RoW | Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent | Zydus Therapeutics Inc. | Nonalcoholic Steatohepatitis, Fibrosis | 07/25 | 07/25 | | |
NCT03617263: Saroglitazar Magnesium 4 Mg in the Treatment of NAFLD in Women with PCOS (EVIDENCES VII) |
|
|
| Active, not recruiting | 2 | 60 | US, RoW | Saroglitazar Magnesium 4 mg Tablet, Not any, Placebo | Zydus Therapeutics Inc. | Non-alcoholic Fatty Liver Disease in Women with PCOS | 11/24 | 11/24 | | |
NCT06398808: A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates |
|
|
| Completed | 2 | 24 | RoW | Arm1, Arm 2 | Zydus Lifesciences Limited | Ulcerative Colitis | 11/24 | 11/24 | | |
NCT05981040: Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis |
|
|
| Completed | 2 | 24 | RoW | ZYIL1 capsules 25 mg and 50 mg Placebo, ZYIL1 capsules 50 mg and 25 mg Placebo, ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg, Matching placebo 25 mg and Matching placebo 50 mg | Zydus Lifesciences Limited | Amyotrophic Lateral Sclerosis | 06/24 | 06/24 | | |
SARONAPLUS, NCT05211284: Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US |
|
|
| Terminated | 2 | 4 | US | Saroglitazar Magnesium 4 mg, Placebo | Zydus Therapeutics Inc. | Nonalcoholic Fatty Liver Disease | 10/23 | 10/23 | | |
ZYFER-1, NCT05911828: A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers |
|
|
| Recruiting | 1 | 36 | RoW | ZY19489 + Ferroquine (FQ), Placebo | Zydus Lifesciences Limited | Uncomplicated Malaria, Asymptomatic Condition, Falciparum Malaria | 02/25 | 05/25 | | |
NCT04469920: Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function |
|
|
| Completed | 1 | 98 | US | Saroglitazar Magnesium 2 mg, Not any, Saroglitazar Magnesium 4 mg | Zydus Therapeutics Inc. | Hepatic Impairment | 03/22 | 03/22 | | |
NCT05045482: Hepatic Impairment with Cirrhosis Due to Cholestatic Liver Disease |
|
|
| Recruiting | 1 | 24 | US | Saroglitazar Magnesium 1 mg, Subjects will be domicile in clinic from Day -1 till Day 5 or Day 7 and from Day 27 through day 29 for PK sampling procedures., Saroglitazar Magnesium 2 mg | Zydus Therapeutics Inc. | Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease | 11/24 | 11/24 | | |
NCT04446507: A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function |
|
|
| Completed | 1 | 32 | US | Saroglitazar magnesium, not any | Zydus Therapeutics Inc. | Renal Impairment | 05/24 | 05/24 | | |
| Momin, Taufik |
| No trials found |
